IMV Inc.

Categories

HEALTH CARE - PharmacyGROWTH CHAMPIONS

About Us

Immunovaccine Inc. is a clinical-stage biopharmaceutical corporation dedicated to making immunotherapy more effective, more broadly applicable, and more widely available to people facing cancer and infectious diseases. Immunovaccine develops T cell activating cancer immunotherapies and infectious disease vaccines based on DepoVax™, the Corporation’s patented platform that provides controlled and prolonged exposure of antigens and adjuvant to the immune system. Immunovaccine has advanced two T cell activation therapies for cancer through Phase 1 human clinical trials and is currently conducting a Phase 1b study with Incyte Corporation assessing lead cancer therapy, DPX-Survivac, as a combination therapy in ovarian cancer. The Corporation is also exploring additional applications of DepoVax™, including DPX-RSV, an innovative vaccine candidate for respiratory syncytial virus (RSV), which has recently completed a Phase 1 clinical trial. Immunovaccine also has ongoing clinical projects to assess the potential of its platform to address malaria and the Zika virus. Connect at www.imvaccine.com.

Images

Gallery Image 3%20Champions.jpg

Rep/Contact Info

Hailey Dewtie
HR Associate
Anna Fryday
Director, Human Resources

Stay Connected

Subscribe to our weekly e-newsletter and receive important updates on Halifax Chamber events, Member benefits and advocacy news.

Contact Us

The Halifax Chamber recognizes that we are in Halifax, or Kjipuktuk, in Mi’kma’ki, the ancestral and traditional lands of the Mi’kmaq people. We acknowledge the Peace & Friendship Treaties signed in this Territory and recognize that we are all Treaty People.

© 2022 Halifax Chamber of Commerce.

Robotics in Healthcare